Jason Butler
Stock Analyst at JMP Securities
(3.66)
# 819
Out of 4,650 analysts
127
Total ratings
44.26%
Success rate
8.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNS Marinus Pharmaceuticals | Downgrades: Market Perform | n/a | $0.37 | - | 3 | Oct 24, 2024 | |
| AQST Aquestive Therapeutics | Reiterates: Market Outperform | $9 | $5.49 | +63.93% | 7 | Oct 8, 2024 | |
| ZVRA Zevra Therapeutics | Initiates: Market Outperform | $17 | $8.05 | +111.18% | 1 | Sep 24, 2024 | |
| RZLT Rezolute | Reiterates: Market Outperform | $7 | $5.63 | +24.33% | 7 | Sep 20, 2024 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $8.06 | +383.87% | 4 | Sep 4, 2024 | |
| CYTK Cytokinetics | Reiterates: Market Outperform | $78 | $52.26 | +49.25% | 12 | Sep 4, 2024 | |
| ATHA Athira Pharma | Downgrades: Market Perform | n/a | $0.49 | - | 7 | Sep 4, 2024 | |
| PGEN Precigen | Maintains: Market Outperform | $14 → $7 | $0.84 | +728.60% | 7 | Aug 15, 2024 | |
| SYRS Syros Pharmaceuticals | Maintains: Market Outperform | $12 → $4 | $2.11 | +89.57% | 3 | Aug 13, 2024 | |
| HOOK HOOKIPA Pharma | Maintains: Market Outperform | $50 → $23 | $3.82 | +502.09% | 3 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $471 → $468 | $554.47 | -15.60% | 5 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $85 → $83 | $17.59 | +371.86% | 7 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $72 → $71 | $50.46 | +40.71% | 12 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $23 | $3.90 | +489.74% | 3 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $13.59 | +39.81% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $39 | $14.74 | +164.59% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $42 → $38 | $23.28 | +63.23% | 7 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $4.15 | +430.12% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.46 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $1,200 | $0.88 | +136,418.77% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $11.58 | +901.73% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $4.05 | +122.22% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $191 → $111 | $2.13 | +5,111.27% | 6 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.17 | - | 1 | Dec 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $24 → $21 | $76.82 | -72.66% | 5 | Aug 8, 2019 |
Marinus Pharmaceuticals
Oct 24, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.37
Upside: -
Aquestive Therapeutics
Oct 8, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $5.49
Upside: +63.93%
Zevra Therapeutics
Sep 24, 2024
Initiates: Market Outperform
Price Target: $17
Current: $8.05
Upside: +111.18%
Rezolute
Sep 20, 2024
Reiterates: Market Outperform
Price Target: $7
Current: $5.63
Upside: +24.33%
GH Research
Sep 4, 2024
Reiterates: Market Outperform
Price Target: $39
Current: $8.06
Upside: +383.87%
Cytokinetics
Sep 4, 2024
Reiterates: Market Outperform
Price Target: $78
Current: $52.26
Upside: +49.25%
Athira Pharma
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.49
Upside: -
Precigen
Aug 15, 2024
Maintains: Market Outperform
Price Target: $14 → $7
Current: $0.84
Upside: +728.60%
Syros Pharmaceuticals
Aug 13, 2024
Maintains: Market Outperform
Price Target: $12 → $4
Current: $2.11
Upside: +89.57%
HOOKIPA Pharma
Jul 26, 2024
Maintains: Market Outperform
Price Target: $50 → $23
Current: $3.82
Upside: +502.09%
May 10, 2024
Maintains: Market Outperform
Price Target: $471 → $468
Current: $554.47
Upside: -15.60%
May 9, 2024
Maintains: Market Outperform
Price Target: $85 → $83
Current: $17.59
Upside: +371.86%
May 8, 2024
Maintains: Market Outperform
Price Target: $72 → $71
Current: $50.46
Upside: +40.71%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $23
Current: $3.90
Upside: +489.74%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $13.59
Upside: +39.81%
Mar 12, 2024
Maintains: Outperform
Price Target: $44 → $39
Current: $14.74
Upside: +164.59%
Nov 14, 2023
Maintains: Market Outperform
Price Target: $42 → $38
Current: $23.28
Upside: +63.23%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $4.15
Upside: +430.12%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.46
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $1,200
Current: $0.88
Upside: +136,418.77%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $11.58
Upside: +901.73%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $4.05
Upside: +122.22%
May 5, 2021
Maintains: Market Outperform
Price Target: $191 → $111
Current: $2.13
Upside: +5,111.27%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $1.17
Upside: -
Aug 8, 2019
Reiterates: Market Outperform
Price Target: $24 → $21
Current: $76.82
Upside: -72.66%